CVID-associated TACI mutations affect autoreactive B cell selection and activation
Romberg N, Chamberlain N, Saadoun D, Gentile M, Kinnunen T, Ng YS, Virdee M, Menard L, Cantaert T, Morbach H, Rachid R, Martinez-Pomar N, Matamoros N, Geha R, Grimbacher B, Cerutti A, Cunningham-Rundles C, Meffre E. CVID-associated TACI mutations affect autoreactive B cell selection and activation. Journal Of Clinical Investigation 2013, 123: 4283-4293. PMID: 24051380, PMCID: PMC3786721, DOI: 10.1172/jci69854.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, AntinuclearAutoantibodiesB-Cell Activating FactorB-LymphocytesCase-Control StudiesCell ProliferationCells, CulturedCentral ToleranceCommon Variable ImmunodeficiencyDNA-Binding ProteinsGene DosageHeterozygoteHumansLymphocyte ActivationMaleMiddle AgedMutationPeripheral ToleranceProto-Oncogene Proteins c-bcl-6T-Lymphocytes, Helper-InducerToll-Like Receptor 7Toll-Like Receptor 9Transmembrane Activator and CAML Interactor ProteinConceptsCommon variable immune deficiencyB cell activationAutoreactive B cellsTACI mutationsCell activationAntinuclear antibodiesCVID patientsB cellsFollicular helper cellsCentral B cell toleranceVariable immune deficiencyB cell responsivenessB-cell lymphoma 6B cell toleranceTumor necrosis factor receptorNecrosis factor receptorB cell selectionAutoimmune complicationsAutoimmune manifestationsPrimary diseaseAntibody deficiencyImmune toleranceHelper cellsTolerance checkpointsImmune deficiency